CGTX Insider Trading

Insider Ownership Percentage: 20.55%
Insider Buying (Last 12 Months): $57,100.00
Insider Selling (Last 12 Months): $0.00

Cognition Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Cognition Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cognition Therapeutics Share Price & Price History

Current Price: $2.77
Price Change: Price Decrease of -0.28 (-9.18%)
As of 12/9/2022 05:13 PM ET

This chart shows the closing price history over time for CGTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Cognition Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2022Ellen B RichstoneDirectorBuy10,000$2.65$26,500.0010,000View SEC Filing Icon  
11/15/2022Lisa RicciardiCEOBuy12,000$1.30$15,600.0024,500View SEC Filing Icon  
11/15/2022Peggy WallaceDirectorBuy12,500$1.20$15,000.0037,961View SEC Filing Icon  
10/13/2021Peggy WallaceDirectorBuy3,000$12.00$36,000.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Cognition Therapeutics (NASDAQ:CGTX)

23.06% of Cognition Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CGTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Cognition Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2022Captrust Financial Advisors50,000$95K0.0%N/A0.220%Search for SEC Filing on Google Icon
11/16/2022Baird Financial Group Inc.40,786$77K0.0%+100.0%0.180%Search for SEC Filing on Google Icon
11/15/2022State Street Corp14,650$28K0.0%N/A0.065%Search for SEC Filing on Google Icon
11/15/2022Two Sigma Investments LP24,407$46K0.0%N/A0.107%Search for SEC Filing on Google Icon
11/15/2022Vanguard Group Inc.401,203$0.76M0.0%+465.7%1.767%Search for SEC Filing on Google Icon
11/15/2022Carlson Capital L P100,000$0.19M0.0%N/A0.440%Search for SEC Filing on Google Icon
11/14/2022Worth Venture Partners LLC200,188$0.38M0.2%-12.3%0.881%Search for SEC Filing on Google Icon
11/10/2022Rock Creek Group LP50,000$95K0.0%-37.3%0.220%Search for SEC Filing on Google Icon
11/2/2022Voss Capital LLC219,100$0.42M0.1%-29.2%0.965%Search for SEC Filing on Google Icon
11/1/2022P.A.W. Capital Corp100,000$0.19M0.3%-25.9%0.440%Search for SEC Filing on Google Icon
10/12/2022Wealth Alliance Advisory Group LLC18,500$35K0.0%N/A0.081%Search for SEC Filing on Google Icon
8/13/2022Voss Capital LLC309,472$0.65M0.2%+1,070.5%1.363%Search for SEC Filing on Google Icon
8/13/2022Prosight Management LP120,198$0.25M0.2%-49.9%0.532%Search for SEC Filing on Google Icon
8/11/2022Perigon Wealth Management LLC122,846$0.26M0.0%N/A0.544%Search for SEC Filing on Google Icon
8/8/2022Rock Creek Group LP79,751$0.17M0.0%+201.6%0.353%Search for SEC Filing on Google Icon
8/1/2022Castle Wealth Management LLC43,380$92K0.1%N/A0.192%Search for SEC Filing on Google Icon
7/19/2022Commonwealth Equity Services LLC214,961$0.45M0.0%+1,447.6%0.951%Search for SEC Filing on Google Icon
7/13/2022P.A.W. Capital Corp135,000$0.29M0.4%+12.5%0.597%Search for SEC Filing on Google Icon
5/17/2022Worth Venture Partners LLC175,366$0.47M0.2%N/A0.776%Search for SEC Filing on Google Icon
5/17/2022Prosight Management LP240,080$0.66M0.4%-20.5%1.062%Search for SEC Filing on Google Icon
5/13/2022Frontier Wealth Management LLC50,000$0.15M0.0%N/A0.221%Search for SEC Filing on Google Icon
5/13/2022Nantahala Capital Management LLC196,402$0.54M0.0%-6.3%0.869%Search for SEC Filing on Google Icon
5/13/2022Baird Financial Group Inc.20,393$56K0.0%N/A0.090%Search for SEC Filing on Google Icon
5/4/2022Commonwealth Equity Services LLC13,890$38K0.0%N/A0.061%Search for SEC Filing on Google Icon
4/26/2022Diligent Investors LLC30,520$84K0.0%N/A0.135%Search for SEC Filing on Google Icon
4/26/2022Kestra Advisory Services LLC238,666$0.66M0.0%+150.9%1.057%Search for SEC Filing on Google Icon
4/21/2022P.A.W. Capital Corp120,000$0.33M0.3%+20.0%0.531%Search for SEC Filing on Google Icon
4/14/2022Bangor Savings Bank18,496$51K0.0%N/A0.082%Search for SEC Filing on Google Icon
2/10/2022B. Riley Financial Inc.30,904$0.20M0.0%N/A0.140%Search for SEC Filing on Google Icon
2/10/2022American Financial Group Inc.205,000$1.30M0.4%N/A0.930%Search for SEC Filing on Google Icon
2/10/2022AIGH Capital Management LLC25,496$0.16M0.0%N/A0.116%Search for SEC Filing on Google Icon
2/10/2022P.A.W. Capital Corp100,000$0.63M0.6%N/A0.454%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Cognition Therapeutics logo
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Read More on Cognition Therapeutics

Today's Range

Now: $2.77
Low: $2.54
High: $3.15

50 Day Range

MA: $1.90
Low: $1.17
High: $3.51

52 Week Range

Now: $2.77
Low: $1.07
High: $8.83

Volume

240,153 shs

Average Volume

223,981 shs

Market Capitalization

$62.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Who are the company insiders with the largest holdings of Cognition Therapeutics?

Cognition Therapeutics' top insider investors include:
  1. Peggy Wallace (Director)
  2. Lisa Ricciardi (CEO)
  3. Ellen B Richstone (Director)
Learn More about top insider investors at Cognition Therapeutics.

Who are the major institutional investors of Cognition Therapeutics?

Cognition Therapeutics' top institutional shareholders include:
  1. Vanguard Group Inc. — 1.77%
  2. Voss Capital LLC — 0.96%
  3. Worth Venture Partners LLC — 0.88%
  4. Carlson Capital L P — 0.44%
  5. P.A.W. Capital Corp — 0.44%
  6. Rock Creek Group LP — 0.22%
Learn More about top institutional investors of Cognition Therapeutics stock.

Which institutional investors are selling Cognition Therapeutics stock?

Within the last quarter, CGTX stock was sold by these institutional investors:
  1. Voss Capital LLC
  2. P.A.W. Capital Corp
  3. Rock Creek Group LP
  4. Worth Venture Partners LLC

Which institutional investors are buying Cognition Therapeutics stock?

During the last quarter, CGTX stock was bought by institutional investors including:
  1. Vanguard Group Inc.
  2. Carlson Capital L P
  3. Captrust Financial Advisors
  4. Two Sigma Investments LP
  5. Baird Financial Group Inc.
  6. Wealth Alliance Advisory Group LLC
  7. State Street Corp
During the previous year, these company insiders have bought Cognition Therapeutics stock:
  1. Peggy Wallace (Director)
  2. Lisa Ricciardi (CEO)
  3. Ellen B Richstone (Director)
Learn More investors buying Cognition Therapeutics stock.